Cipla gets CDSCO panel nod to study Rizatriptan Benzoate Orally Disintegrating Tablet

Published On 2022-08-04 12:30 GMT   |   Update On 2022-08-04 12:30 GMT
Advertisement

Granting approval to conduct bioequivalence (BE) study of Rizatriptan Benzoate Orally Disintegrating Tablets 5mg, the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has recommended the drug major Cipla to reduce sampling time points and blood volume during the study.

This came in wake of proposal presented by the drug major Cipla to manufacture and market Rizatriptan Benzoate Orally Disintegrating Tablets 5mg along with bioequivalence (BE) study protocol.

Advertisement

For more details, check out the full story on the link below:

Cipla Secure CDSCO Panel Nod To Study Rizatriptan Benzoate Orally Disintegrating Tablet


Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News